New combo therapy aims to boost CAR T-Cell power against lymphoma
NCT ID NCT04257578
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding the drug acalabrutinib to CAR T-cell therapy can improve treatment for certain B-cell lymphomas. Acalabrutinib blocks cancer growth pathways, while the CAR T-cells are engineered to attack lymphoma cells. The study involves 23 adults and primarily checks for safety and side effects, while also looking at how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- acalabrutinib (a targeted drug) and axicabtagene ciloleucel (a CAR T-cell therapy)
- What this could lead to
- If successful, this combination could improve how well CAR T-cell therapy works for B-cell lymphoma, potentially leading to better disease control and longer remission.
- What could go wrong
- This is an early-phase trial with only 23 participants, so results may not apply widely. There are risks of serious side effects like cytokine release syndrome and neurotoxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- Triple-Drug cocktail aims to boost remission in follicular lymphoma
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- New drug combo aims to tame aggressive lymphoma in frail patients
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma